Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 39.15
- Piotroski Score 5.00
- Grade Buy
- Symbol (KRYS)
- Company Krystal Biotech, Inc.
- Price $178.43
- Changes Percentage (1.42%)
- Change $2.5
- Day Low $178.36
- Day High $178.97
- Year High $219.34
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in Phase I/II clinical stage for treating wrinkles and other presentations of aged or damaged skin; KB407 that is in preclinical stage for cystic fibrosis; and KB104, which is in preclinical stage for netherton syndrome. Its discovery stage product candidates include KB5xx for treating chronic skin diseases, KB3xx to treat aesthetic skin conditions, and KB3xx product. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/03/2024
- Fiscal Year End N/A
- Average Stock Price Target $205.50
- High Stock Price Target $220.00
- Low Stock Price Target $133.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $2.18
- Trailing P/E Ratio 75.42
- Forward P/E Ratio 75.42
- P/E Growth 75.42
- Net Income $10.93 M
Income Statement
Quarterly
Annual
Latest News of KRYS
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Krystal Biotech, Inc. (KRYS): Promising Pipeline or Risky Gamble?
The article discusses the performance of Krystal Biotech, Inc. in comparison to other worst booming stocks according to short sellers. It also provides insights from Tom Lee on the market's trajectory...
By Yahoo! Finance | 1 week ago -
Stocks Showing Market Leadership: Krystal Biotech Earns 93 RS Rating
Discover why institutional support matters in stock trading with IBD's exclusive RS rating, which rates market leadership on a scale of 1 to 99 based on price performance over 52 weeks. Stocks with an...
By Investor's Business Daily | 3 weeks ago -
Krystal Keith Says Listening to Dad Toby Keith's Music 'Constantly' Helps Her 'Hold onto the Gratitude' (Exclusive)
Krystal Keith, daughter of late country legend Toby Keith, will perform his song "Don't Let the Old Man In" in a tribute concert. The concert will feature other stars and pay homage to Toby's legacy. ...
By PEOPLE.com | 1 month ago
